Last reviewed · How we verify
ATM Kinase Inhibitor AZD1390
ATM kinase inhibitor
ATM kinase inhibitor Used for Glioblastoma.
At a glance
| Generic name | ATM Kinase Inhibitor AZD1390 |
|---|---|
| Also known as | AZD-1390, AZD1390 |
| Sponsor | Children's Oncology Group |
| Drug class | ATM kinase inhibitor |
| Target | ATM |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD1390 is a potent and selective inhibitor of ataxia-telangiectasia mutated (ATM) kinase, which plays a critical role in the DNA damage response pathway.
Approved indications
- Glioblastoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma (PHASE1)
- AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients (EARLY_PHASE1)
- Sarcomas and DDR-Inhibition; a Combined Modality Study (PHASE1)
- A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer (PHASE1)
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (PHASE1)
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer (PHASE1)
- AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATM Kinase Inhibitor AZD1390 CI brief — competitive landscape report
- ATM Kinase Inhibitor AZD1390 updates RSS · CI watch RSS
- Children's Oncology Group portfolio CI